Table 8. Incidence of infections with... | American Society of Hematology

Table 8.

Incidence of infections with BCMA-directed CAR T-cell therapies as reported in clinical studies (A) and in retrospective real-world series (B)

8A
Clinical studies	Number of patients	Time frame (mo)	Overall grade patient number (%)	Grade 3/4 patient number (%)	Bacterial patient number (%)	Viral patient number (%)	Fungal patient number (%)	Not specified patient number (%)
KarMMa-1⁷³	33	6	14 (42)	2 (6)	NR	NR	NR	NR
KarMMa-2⁷⁴	128	24	88 (69)	28 (22)	19 (15)	35 (27)	10 (8)	63 (9)
KarMMa-3⁶¹	254	24	146 (58)	61 (24)¹	NR	NR	NR	NR
Cartitude-1⁷⁵	97	12	56 (58)	19 (20)	NR	NR	NR	NR
Cartitude-4⁶⁰	208	Median FU 15.9 mo	129 (62)	56 (27%)²	NR	NR	NR	NR

8A
Clinical studies	Number of patients	Time frame (mo)	Overall grade patient number (%)	Grade 3/4 patient number (%)	Bacterial patient number (%)	Viral patient number (%)	Fungal patient number (%)	Not specified patient number (%)
KarMMa-1⁷³	33	6	14 (42)	2 (6)	NR	NR	NR	NR
KarMMa-2⁷⁴	128	24	88 (69)	28 (22)	19 (15)	35 (27)	10 (8)	63 (9)
KarMMa-3⁶¹	254	24	146 (58)	61 (24)¹	NR	NR	NR	NR
Cartitude-1⁷⁵	97	12	56 (58)	19 (20)	NR	NR	NR	NR
Cartitude-4⁶⁰	208	Median FU 15.9 mo	129 (62)	56 (27%)²	NR	NR	NR	NR

Additionally, grade 5, n = 11 (4%).

Grade 5 infections not specifically reported, n = 10 died due to adverse events, and 7 died due to COVID-19 (3.4).

FU, follow-up.

Adapted with permission from Kampouri et al.⁵⁹